Osteopore reaches record revenue as new implant markets open

Record quarterly revenue reaches A$859,000

Osteopore Limited (ASX:OSX) has put a new high-water mark on its sales chart, reporting Q3 CY26 revenue of A$859,000. The result rose 27% from the previous quarter and 6% from the same period a year earlier, extending a recovery from the company’s A$754,000 Q1 revenue and A$812,000 Q2 revenue.

The improvement is commercially encouraging, but the quarterly report does not provide revenue guidance, profitability or the value of the distribution arrangements announced during the period. The more important test now is whether newly opened markets begin contributing repeat orders rather than simply adding to Osteopore’s addressable territory.

Middle Eastern access moves into registration

Osteopore has commenced product registration across Saudi Arabia, the United Arab Emirates, Oman, Qatar and Bahrain under its orthopaedic arrangement with Al-Umnia Medical LLC. The company announced the five-country deal in August, targeting a Gulf orthopaedic devices market it values at about US$897.5 million in 2025 and forecasts will reach US$1.55 billion by 2034.

The filing also highlights Saudi Arabian craniofacial access through Osteopore’s distribution partnership with Zimmer Biomet. That relationship is distinct from the Al-Umnia orthopaedic arrangement, and the report describes Saudi Arabia as part of Zimmer’s EMEA distribution footprint. Neither arrangement is accompanied by disclosed sales targets or contract values. The five-country Middle East deal therefore remains a market-entry milestone, with registration and commercial conversion still ahead.

Thailand and Hainan add commercial proof points

Osteopore has secured Thai market access for its full orthopaedic product range and established supply-chain and logistics support through DCH Auriga. The company cites a Thai orthopaedic devices market worth US$749 million in 2025 and projected to reach US$1.5 billion by 2033, although the report does not quantify the opportunity available to Osteopore specifically.

In China, the company delivered and implanted its first customised orthopaedic device in Hainan after receiving regulatory approval in May. The implant was used to reconstruct a 12cm upper-limb bone defect after tumour resection at the Hainan branch of Shanghai Ruijin Hospital. It is a tangible step beyond the Hainan FDA approval, but a single procedure does not yet establish the scale or pace of future demand.

Cash burn falls while convertible funding remains available

Net cash used in operating activities was A$559,000 during the quarter, down 19% from A$691,000 in Q2. Osteopore attributed the improvement to higher customer receipts and lower manufacturing, operating and research and development payments, partly offset by higher administration and corporate costs.

Cash stood at A$712,000 at 30 September, while A$6 million had been drawn from a redeemable convertible note facility with a total nominal value of up to A$20 million. That leaves A$14 million available, although the notes carry a conversion mechanism based on 80% of the average closing price over a selected five-day period. The facility offers substantial stated funding capacity, but any future drawdowns or conversions would remain relevant to the company’s capital structure.

Neurosurgical guide awaits funding for clinical evaluation

Osteopore also completed the design, prototyping and simulated dry-bone testing phases of a ventricular catheter guide developed with Singapore’s National University Hospital. The company said the project team is seeking additional funding to progress the device into clinical evaluation, so the milestone is not yet a clinical or commercial launch.

The next quarter should reveal whether the expanded market footprint begins to translate into a more durable sales trajectory. Registration progress, repeat Hainan procedures, operating cash use and the company’s decisions around its remaining convertible capacity will matter more than the headline count of new territories.